Modifier genes play a significant role in the phenotypic expression of PKD1

被引:79
作者
Fain, PR
McFann, KK
Taylor, MRG
Tison, M
Johnson, AM
Reed, B
Schrier, RW
机构
[1] Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, Denver, CO 80262 USA
[2] Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA
关键词
polycystic kidney disease; modifier genes; PKD1; mutations; genetic background;
D O I
10.1111/j.1523-1755.2005.00203.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Polycystic kidney disease type 1 (PKD1) is characterized by extreme variation in the severity and progression of renal and extrarenal phenotypes. There are significant familial phenotype differences; but it is not clear if this is due to differences in PKD1 mutations, differences in genetic background, or both. Methods. A total of 315 affected relatives (83 PKD1 families) without end-stage renal disease (ESRD) were evaluated for disease markers, including renal volume, creatinine clearance, proteinuria, liver cysts, and hypertension. Of these patients, 19% progressed to ESRD within 1 to 10 years after the initial examination. Nested analysis of variance was used to investigate interfamilial and intrafamilial differences in these phenotypes. Heritability analyses were used to estimate the effect of the genetic background on phenotypic variability. The age of onset of ESRD was also analyzed with an additional 389 family members from the same PKD1 families without clinical evaluation but with data on age of onset of ESRD (or age without ESRD). Results. There were significant phenotype differences between patients with the same mutation and different genetic backgrounds. The phenotypic variation between patients with different mutations and different genetic backgrounds was not significantly greater than the variation between patients with the same mutation and different genetic backgrounds. However, when the 389 family members were included, both the mutation and modifier genes had significant effects on the age of onset of ESRD. Inherited differences in genetic background were estimated to account for 18% to 59% of the phenotypic variability in PKD1 disease markers in patients prior to ESRD and in the subsequent progression to ESRD (43% heritability) in the 315 patients who were clinically evaluated. Conclusion. Modifier loci in the genetic background are important factors in inter- and intrafamilial variability in the phenotypic expression of PKD1. The extreme intrafamilial phenotype differences are consistent with the hypothesis that one or a few modifier genes have a major effect on the progression and severity of PKD1.
引用
收藏
页码:1256 / 1267
页数:12
相关论文
共 59 条
[1]   Multipoint quantitative-trait linkage analysis in general pedigrees [J].
Almasy, L ;
Blangero, J .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (05) :1198-1211
[2]   Variance components analysis for genetic linkage of time to onset for disease [J].
Amos, CI ;
Shete, S ;
Gu, XJ .
GENETIC EPIDEMIOLOGY, 2001, 21 :S768-S773
[3]   Association of the angiotensin I converting enzyme gene deletion polymorphism with early onset of ESRF in PKD1 adult polycystic kidney disease [J].
Baboolal, K ;
Ravine, D ;
Daniels, J ;
Williams, N ;
Holmans, P ;
Coles, GA ;
Williams, JD .
KIDNEY INTERNATIONAL, 1997, 52 (03) :607-613
[4]   Characterization of a major modifier locus for polycystic kidney disease (Modpkdr1) in the Han:SPRD(cy/+) rat in a region conserved with a mouse modifier locus for Alport syndrome [J].
Bihoreau, MT ;
Megel, N ;
Brown, JH ;
Kränzlin, B ;
Crombez, L ;
Tychinskaya, Y ;
Broxholme, J ;
Kratz, S ;
Bergmann, V ;
Hoffman, S ;
Gauguier, D ;
Gretz, N .
HUMAN MOLECULAR GENETICS, 2002, 11 (18) :2165-2173
[5]  
*CAS W RES U, 2004, STAT AN GEN EP
[6]   THE RENIN-ANGIOTENSIN ALDOSTERONE SYSTEM AND AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY-DISEASE [J].
CHAPMAN, AB ;
JOHNSON, A ;
GABOW, PA ;
SCHRIER, RW .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (16) :1091-1096
[7]  
COX DR, 1972, J R STAT SOC B, V34, P187
[8]  
DALGAARD OZ, 1957, ACTA MED SCAND, V328, P1
[9]  
Ecder T, 2001, J AM SOC NEPHROL, V12, P194, DOI 10.1681/ASN.V121194
[10]  
EMAMIAN SA, 1995, ACTA RADIOL, V36, P399